Tuesday, 21 July 2020

Worldwide Viral Gastroenteritis Market Top 10 Players Universal Analysis, Industry Demand And 2023 Forecast

 Market Synopsis of the Global Viral Gastroenteritis Market
Viral gastroenteritis, also known as stomach flu, is inflammation of the lining of the stomach, small intestine, and large intestine. There are a number of viruses leading viral gastroenteritis such as norovirus, rotavirus, astrovirus and enteric adenovirus. Norovirus and rotavirus are the most common causes of this disease. This disease is transmitted through direct contact with the patient, and contaminated water or food. The main focus of treating the disease is rehydration by drinking enough water or fluids.
The market for viral gastroenteritis is driven by an increasing prevalence of gastrointestinal diseases, availability of cost effective treatment and extensive research and development activities in internal medicine Furthermore, there is an increasing demand for the new drugs for the treatment of the disease.
The global viral gastroenteritis market size is expected to grow at a CAGR of 7.5% during the forecast period.
Bacterial resistance to commonly used antibiotics such as penicillin and amoxicillin may be the leading restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrant in the market.
According to the World Health Organization (WHO), diarrheal diseases are a major cause of hospitalizations and child deaths globally.
Key Players in the Global Viral Gastroenteritis Market Some of the key players in this market are Valeant Pharmaceuticals International Inc. (U.S.), Janssen Global Services, LLC U.S.), Takeda Pharmaceutical (Japan), Bayer AG (Germany), Sanofi (France), Allergan (Ireland), GlaxoSmithKline (U.S.), Abbott (U.S.),  and AstraZeneca (U.K).
Segments                                                                                                                                         
The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.
On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.
On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.
On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.
On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.
On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.
Regional Analysis of the Global Viral Gastroenteritis Market              
America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center For Disease Control And Prevention (CDC), each year on average in the United States, there are 19 to 21 million cases of acute gastroenteritis.
Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.
In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostic tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will propel the growth of the Asia Pacific market.
The Middle East & Africa also show a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection.
Posted by at No comments:

Homeopathic Medicine Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Insights
The market for homeopathy has expanded remarkably because of the increasing demand for natural remedies. Growing prevalence of chronic and lifestyle-related diseases such as obesity, diabetes, cancer, and fertility issues have led to a faster adoption of alternative medical treatments such as homeopathic medicine. However, the market is regulated by strict laws pertaining to the application of homeopathy in some developed nations like the U.K. and Germany. Meanwhile, many developing economies pose a high possibility for development attributing to the cultural propinquity for natural medication.
The Worldwide Homeopathic Medicine industry is expected to grow at a CAGR of 12.5% during the forecast period. The global homeopathic medicine market is expected to show sharp growth over the forecast period. Rising prevalence of chronic disease and increasing demand for medicines from natural sources and overall increase in the awareness about medicines and treatment options in homeopathy drive the market growth. Furthermore, homeopathy is gaining attention in many of the emerging market throughout the globe. Lack of awareness about homeopathy in developing countries may act as a barrier for the market growth.
Growing incidences of lifestyle-related and chronic diseases such as cancer, diabetes, obesity, and fertility problems have led to the increased adoption of alternative medical treatments such as homeopathic medicine, this driving market demand. The homeopathic medicine market is restrained by the implementation of strict regulations surrounding the use of homeopathy in certain developed economies such as Germany and the U.K. Meanwhile; emerging economies carry a high potential for growth due to the cultural affinity for natural medication in several fast emerging markets.
Regional Analysis
Led by the U.S, the Americas account for the largest share of the global market due to the high awareness regarding homeopathic medicine. Highly expensive healthcare often encourages patients to adopt homeopathic medicine. Moreover, the region is witnessing a rising occurrence in lifestyle-related diseases which further facilitate increased demand for homeopathic medicine.
Europe accounts for the second largest share due to the high number of homeopathic practitioners available in the region. U.K leads the regional market with the most significant share. The European region has widespread use of homeopathic medicine for day to day use in assisting the treatment of minor health problems.
In Asia Pacific, rising demand for alternative medicine such as homeopathy and Ayurveda, the prevalence of chronic diseases such as diabetes and obesity and increasing in the adoption of medicines from natural sources drive the market growth. Homeopathic Medicine Market Size in India is the largest for in Asia Pacific owing to its largest homeopathic infrastructure in the world and increasing in the number of homeopathic medical institutes and research centers.  Japanese Homoeopathic Medical Association is engaged in the academic research, promotion and international exchange of homoeopathy in Japan. Whereas, homeopathy is relatively unknown and moderately practiced in China.
Key Players
The competitive analysis of the market in MRFRs report records the strategies and market positions of leading market players such as Natural Health Supply, Boiron, HomeoLab USA, Hyland's Homeopathic, SBL, Nelson & Co. Ltd., and Hahnemann Laboratories Inc.
Latest Industry News
  • NHS funded homeopathic treatments have been cut off with exceptions to be considered on a case by case basis.
  • Indian homeopathy start-up Welcomecure has raised undisclosed investment from Bollywood Thier association with the brand is expected to increase demand.
Market Segmentation
The global homeopathic medicine market is segmented on the basis of type, indication, and end users.
On the basis of drugs, market is segmented into plants based, animal based and mineral based. Plant based is further segmented into Arnica montana, Bryonia alba, Cinchona officinalis, Pulsatilla nigricans, Rhus tox, Symphytum. Animal based is further segmented into Latrodectus mactans, Tarentula Hispania, Tarentula cubensis, Naja tripudians, Vipera, Sepia, and Cantharis. Mineral based is further segmented into Calcarea carbonica, Phosphorus, Calcarea phosphorica, Natrum muriaticuma and others. Other segments are Nosodes, Sarcodes and Imponderabilia.
On the basis of application, the market is segmented into skin & hair, reproductive health, lifestyle disorders, bones, joints, and muscles diseases, brain and nerves disorders, respiratory diseases, childhood diseases, hormonal disorders and others.
On the basis of end user, the market is divided into hospitals, homeopathic clinics, and others.
Posted by at No comments:

International Healthcare Revenue Cycle Management Market 2019 Estimation And Forecasts Up To 2027

Market Scenario
The report covers the latest trends impacting the market to provide the most accurate forecasts and predictions. By correlating the historical data with upcoming market dynamics, our analysts can make highly astute projections. MRFR’s report includes a thorough analysis of the global healthcare revenue cycle management market segmented according to type, application, end-user, and region. Growth opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.
The global healthcare revenue cycle management market size is touted to exhibit a healthy 12.2% CAGR during the assessment period (2017-2027), as per a new market report by Market Research Future (MRFR).
The rising costs of surgeries and overall healthcare has induced the need for hospitals to lean towards technology to reduce the burden. Healthcare revenue cycle management (RCM) is a system in the healthcare cycle which relies on electronic health records (EHRs) and automation to expedite outpatient billing and reduce wait times. The growing numbers of hospitals and clinics, rising adoption rate of RCM software, recovery audits, and preference for integrated healthcare systems are factors expected to drive market demand during the forecast period.
Regional Analysis:
The geographical analysis of the market covers namely the Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA).
The Americas take the onus of generating the maximum revenue as the region has this tendency to rely heavily on advanced technology. Advanced infrastructure accommodates such a wide-spread implementation of RCM software which benefits all. In addition, the market is profiting much from several major players presence in the segment, along with a scheduled substantial healthcare expenditure every year.
Europe is holding the second position, and it can be attributed to increasing government support in research and development. Other features such as well-developed healthcare infrastructure and considerable healthcare funding are quite similar in their impact to that of the Americas.
The APAC is all set to register the fastest Healthcare Revenue Cycle Management market growth. Emerging economies of the region are changing the healthcare sector remarkable, and many of them are evolving as a medical tourism hub which as a consequence, is assertively impacting the global RCM market. However, the MEA is still lagging much behind as the region has quite a few poor and slow developing countries.
Segmentation:
Based on the product type, the market can be segmented into advanced integrated software and standalone software. The advanced integrated software accrues almost 81.4% of the total revenue generated in the market and is blessed with the fastest CAGR of 12.3% during the forecast period.   
Component-based segmentation of the market includes software and services. The software segment is gaining precedence considerably in the global market owing to its applicational ease, and it commanded the largest market share in 2016.
Deployment-wise segmentation comprises on-premise and on-cloud/web-based. On-cloud section is gaining much traction. However, on-premise application held the largest share of the market in 2016 as many still find complete cloud solution a bit difficult to operate.
Based on end-users, the market can be segmented into hospitals and ambulatory services. Hospitals hold the major share, and many rely heavily on its assistance in cases of emergency. 
Browse More Healthcare IT Reports @
Detailed Table of Contents:
1.Report Prologue
2.Introduction
2.1 Scope Of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
  1. Research Methodology
3.1 Primary Research
3.2 Secondary Research
3.3 Market Size Estimation
3.3.1 Market Share Analysis
3.4 Market Pricing Approach
  1. Market Dynamics
4.1 Drivers
4.1.1 Increasing Adoption Of RCM Software
4.1.2 Inclination Towards Integrated Healthcare System
4.1.3 Increase In Recovery Audits
4.1.4 Increasing Number Of Hospitals And Healthcare Services
4.2 Restraints
4.2.1 Need Of Well Trained Professionals
4.2.2 High Cost Of RCM Systems
4.3 Opportunities
4.3.1 Developing Healthcare Infrastructure And Supporting IT Infrastructure
4.4 Mega Trends
4.4.1 Adoption Of The Advanced Technology In Healthcare
4.5 Macroeconomic Indicators
  1. Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Inputs
5.1.2 Software Development Processes
5.1.3 Testing
5.1.4 Marketing & Distribution
5.1.5 Post Selling Services
…TOC Continued!

Posted by at No comments:

Oral Thrush Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

Market Scenario
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand  other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of  HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.
Apart from common Oral Thrush symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.
Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high  carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.
Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.
The global oral thrush treatment market is expected to reach USD 9.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Key Players in the Global Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.
Segmentation:

The global oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.
Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.
Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
Globally, the North America market dominates the Oral Thrush market. Factors such as the well-spread awareness among people towards the oral hygiene and healthcare along with the extensive use of medications and high expenditure on the health care and augmenting uptake of new products primarily in the US drive the market growth in the region.
The Europe market accounts for the second-largest market for Oral Thrush owing to the proliferation of healthcare sector, the presence of well-established players and growing healthcare expenditures in the region. Indeed, the resurging economy is the main driving force increasing the market value in the region.
Simultaneously, the presence of the leading global players in the region is some of the key factor substantiating the growth of the regional market. Witnessing a widening uptake of oral hygiene products across the region, the North America market for Oral Thrush is likely to continue its dominance throughout the assessment period.  The North American market significantly contributing to the GDP is expected to register a significant CAGR during the forecast period.
The Europe healthcare industry is currently booming given the increasing number of medical professionals and growing awareness in the region. Moreover, the high influence of media and the rise in the awareness regarding oral hygiene especially in the countries such as Germany and France drive the European oral thrush market.
The Asia Pacific Oral Thrush market emerging as the fastest growing market accounts for a substantial market share on the global platform. Factors such as the proliferation of healthcare sector in populous countries such as India and China substantiate the market growth in the region. 
Furthermore, factors such as augmenting demand for high standards and high-quality oral care products along with the growing technological advancement are estimated to increase the market scope, boosting the demand for effective oral care treatments in the region.
Posted by at No comments:

Africa Malaria Diagnosis & Treatment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Synopsis of Africa Malaria Diagnosis & Treatment Market:
Malaria is an infectious disease caused by parasitic protozoa of the Plasmodium type. The symptoms include fever, fatigue, vomiting, and severe headaches and may lead to seizures, coma, or even death if untreated. Malaria is primarily a disease of the tropical and subtropical regions. The carrier of malaria is the female anopheles mosquito and hence there is a seasonal variation in the cases of malaria. Most cases of malaria are caused by P. falciparum because other types of plasmodium such as P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
According to World Health Organization (WHO), the global incidence of malaria between 2010 and 2015, fell by 21% and the malaria mortality fell by 29%. However the African region carries a disproportionately high share of the global malaria burden and accounted for 90% of malaria cases and 92% of malaria deaths worldwide and sub-Saharan Africa accounted for 76% of malaria cases and 75% deaths globally.
Thus, unmet medical needs is the single most important driver of malaria. Other important market drivers are the hot and humid climatic conditions of certain parts of Africa, presence of population groups at higher risk of contracting malaria such as infants, children under 5 years of age, patients with low immunity such as those with HIV/AIDS, mobile populations and travelers.
The growth of government programs against malaria and the support given by international bodies such as WHO is also a market driver. The market barriers include high cost of imported malaria diagnostic kits, low penetration of healthcare in Africa, low per capita income, low number of healthcare professionals in Africa etc. The political causes include massive corruption, low political power of citizens especially in nondemocratic nations, civil war in regions such as Malawi etc.
Taking all factors into consideration, we expect the Africa malaria  diagnosis market to reach around $ 2418.92 million from $ 550 million in 2017, by the end of the forecast period at a CAGR of ~ 28.0 %. While the malaria treatment market will grow by a CAGR of 8.1% to reach around $ 7180.7 million from $ 4500.0 million in 2016.

Study Objectives for Africa Malaria Diagnosis & Treatment Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Africa malaria diagnosis & treatment market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments for Africa malaria diagnosis & treatment market
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by product type, by technique, malarial parasite and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments.
Intended Audience
  • Malaria Diagnostics Manufacturers and Suppliers
  • Medical Drugs Manufacturers and Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations

Key Players for Africa Malaria Diagnosis & Treatment Market:
Some of the key players in this market are: Alere Inc., Access Bio Inc., Premier Medical Corporation, Beckman Coulter/Danaher, bioMerieux, Novartis Diagnostics, Siemens Healthcare, Bio-Rad Laboratories, Cipla Inc., Ipca Laboratories Ltd., Uni-Med India, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sanofi among others.

Segments:
Africa Malaria Diagnosis & Treatment Market has been segmented on the basis of technique which comprises rapid diagnostic tests (RDT’S), molecular diagnostics and microscopy. On the basis of malarial parasite; market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale.

Regional Analysis of Africa Malaria Diagnosis & Treatment Market:
The healthcare sector of Africa is divided between private and state. The public healthcare expenditure accounts for approximately 48 % of total health expenditure in 2014 with variation in different countries. Local manufacturing represents a poor outlook which is limited to consumables and ordinary articles and there are a handful of high tech devices manufacturers. Africa is extremely dependent on imports for medical devices and imports account for approximately 90 % of total market for medical devices and Chinese medical device suppliers dominate the scenario. Among the regions of Africa, South Africa and Egypt account for 40 % of market. Other important nations are Nigeria, Morocco and Algeria. Collaboration with large global companies and technical transfer will remain the key strategy for developing the regional African market as can be seen by the example of China.

The report of Africa Malaria Diagnosis & Treatment Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regionsTop of Form
Posted by at No comments:

U.S. Personalized Medicine Market Sparkling Growth Worldwide Forecasts By 2023

Market Synopsis of U.S. Personalized Medicine Market:
An expert on premium research reports, Market Research Future has added a report titled " U.S. Personalized Medicine Market Research Report - Forecast To 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.
The Personalized Medicine Market is the most recent trend in the multibillion–dollar molecular diagnostics industry. Pharmaceutical and biotechnology companies are increasingly turning to personalized medicine in order to improve the drug development process and also to speed up the approval or sanction of new drugs.

The U.S. Personalized Medicine market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. A factsheet published by the WHO states that about 17.5 million people die due to cancer and other diseases every year, which is about 31% of the deaths across the globe. These alarming statistics shows the obvious reason for growth of market with the U.S. Personalized Medicine market analysis. Major factors driving the U.S. Personalized Medicine market growth include growing occurrence of autoimmune diseases during the forecast period and various other disease.
U.S personalized medicine market is expected to grow at the CAGR of 7.5% during the forecasted period.
Various trends are responsible for influencing the growth trajectory of the US personalized medicine market. Personalized medicine promises enormous potential in the treatment of cancer. Personalized medicine has entered the mainstream in the treatment of oncology diseases and is changing the way such diseases are identified, treated and classified. According to the World Health Organization (WHO), cancer is one of the prime reasons for 31% of the deaths globally and each year about 17.5 Mn people die due to cancer. Surging prevalence of cancer across the US is a prime reason for the growth of the US personalized medicine market.

Strong research & development activities in the field of personalized medicine by industrial, academic, and government agencies continue to remain strong in the region which also supports the growth of the US personalized medicine market.

Increasing incidences of autoimmune diseases stimulate the growth of the US personalized medicine market. Also, the government in the US is extending its support in the form of funding for R&D activities; favorable NIH policies create a conducive environment for the growth of the US personalized medicine market.


Furthermore, a growing number of companies from outside the health industry are entering the personalized medicine space which is likely to provide an impetus to the growth of the US personalized medicine market. 

Industry Updates
  • In December 2018, researchers at the University of Utah developed a novel personalized medicine tool for inherited colorectal cancer syndrome. The results for the same was published in the journal Genetics in Medicine.
  • In December 2018, researchers at the Columbia University have made advancements in personalized medicine that can be helpful in the treatment of kidney diseases.

Segmentation
The US personalized medicine market has been segmented based on product, application, and end user. By product, the US personalized medicine market has been segmented into diagnostic, therapeutics, medical care and nutrition, and wellness and others. The diagnostic and therapeutic segment accounts for the largest share of the market.
By application, the US personalized medicine market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others.
By end user, the US personalized medicine market has been segmented into hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio & health informatics companies, and others. End user-wise, the hospitals segment commands the largest share of the market owing to growing usage in hospitals. The molecular diagnostic laboratories and testing centers segment is the second largest segment.

Competitive Landscape
Personalized medicine is presenting new challenges as well as opportunities to the market players who are continually endeavoring make their mark in the market. Collaborations through mergers, acquisitions, partnerships, and others are key strategies utilized by the market participants to stay competitive and improve their product offerings. Sanofi, Pfizer Inc., Laboratory Corporation of America, Abbott, Becton Dickinson & Co., Quest Diagnostics, GE Healthcare,
CardioDx Inc., Asuragen Inc., Bristol-Myers Squibb, Siemens Healthcare Diagnostics Inc., are the notable players in the US personalized medicine market.
Posted by at No comments:

India CRO Market Forecasts By Industry Drivers, Regions Till 2023

Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period with overview of top cro companies in India.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
The market constraints that can hamper the growth of India CRO market include growing concern for security especially data security and patient security and lack of collaboration between universities and industry etc. Sometimes, some unethical Indian CROs make dishonest comprises which creates trust issues among potential clients for CROs and hurts the market.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The western and southern regions of India hold a strong position in the CRO market due to their better infrastructure, education and salubrious climate. However the northern regions have started growing and catching up due to larger and more diverse genetic pool and the concentration of regulatory bodies in northern India. The faster growth of hospitals in northern India is favoring the CRO market and has led to this shift. The growth of diseases needing specialized care and treatments such as cancer is booming the CRO market of this segment at a faster pace than other segments.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.
Posted by at No comments:
Subscribe to: Posts (Atom)